This Product contains 80mg Klow stack blend, and has undergone testing , with results showing :

50.65mg -GHK ( Glycyl-L-Histidyl-L-lysine )

12.61mg – BPC 157

11.9mg – TB500

11.21mg – KPV

(Testing proof is avaliable on the TESTING page )

Preclinical Animal Research – KLOW Stack Blend

(BPC-157 + TB-500 + GHK-Cu + KPV)

Overall Combination Status (Important Context)

Study objective (meta-context)

To date, there are no controlled animal or human studies evaluating the combined administration of all four peptides (BPC-157, TB-500, GHK-Cu, and KPV) as a unified therapeutic stack.

Instead, the “KLOW stack” is a theoretical multi-pathway construct derived from independent preclinical research on each peptide’s individual effects:

* BPC-157 → gastrointestinal + soft tissue repair biology
* TB-500 / Thymosin Beta-4 → cell migration + wound closure pathways
* GHK-Cu → extracellular matrix remodeling + gene expression modulation
* KPV → inflammatory signalling suppression (α-MSH fragment pathway)

All combination effects are therefore extrapolated, not experimentally validated as a stack.

⸻

Component Preclinical Evidence

1. BPC-157 – Rat Gastrointestinal & Soft Tissue Injury Models

Study objective

Researchers evaluated BPC-157 in rodent models of gastrointestinal injury, tendon damage, and ischemic tissue damage, focusing on cytoprotection and repair acceleration.

⸻

Methods

Rats were exposed to:

* Ethanol-induced gastric lesions
* NSAID-induced ulceration
* Surgical fistula formation (intestinal and colonic models)
* Tendon transection and crush injury models
* Ischemia-reperfusion injury models

BPC-157 was administered systemically (intraperitoneal and oral routes in select studies).

Measured outcomes included:

* Ulcer size reduction
* Tissue histology and epithelial integrity
* Vascular density in injured tissue
* Functional recovery in tendon injury models
* Survival in severe ischemic injury models

⸻

Results

Across models, BPC-157 produced:

* Significant reduction in gastric lesion size and severity
* Accelerated healing of intestinal fistulas and mucosal defects
* Improved epithelial regeneration and barrier restoration
* Enhanced microvascular formation in damaged tissue
* Faster functional recovery in tendon injury models
* Reduced fibrotic disorganisation in healing tissue

Overall profile: strong cytoprotective + angiogenic + tissue repair response in vivo.

⸻

2. TB-500 (Thymosin Beta-4 pathway) – Rodent Wound & Cardiac Injury Models

Study objective

To evaluate the role of Thymosin Beta-4 (TB-500 fragment is derived from its actin-binding domain) in tissue regeneration and injury recovery.

⸻

Methods

Rodent models included:

* Full-thickness dermal wound excision
* Corneal injury models
* Myocardial infarction (mouse cardiac ischemia model)

Administration was systemic or local depending on model.

Measured outcomes:

* Wound closure rate
* Cell migration (keratinocytes, fibroblasts)
* Angiogenesis markers
* Fibrosis and scar formation
* Cardiac functional recovery (MI model)

⸻

Results

TB-500 / Thymosin Beta-4 pathway activation produced:

* Accelerated wound closure in dermal injury models
* Increased cell migration into damaged tissue
* Enhanced angiogenesis and vascular repair signalling
* Reduced fibrotic scar formation in cardiac tissue
* Improved functional recovery after myocardial infarction

Core biological effect: enhanced cell migration + tissue reconstruction dynamics.

⸻

3. GHK-Cu – Rat Wound Chamber Model (Connective Tissue Regeneration)

Study objective

To evaluate GHK-Cu effects on extracellular matrix formation and wound repair signalling in controlled rat injury systems.

⸻

Methods

Rats received subcutaneous wound chambers and were treated with GHK-Cu.

Researchers measured:

* Collagen and protein synthesis
* DNA content (cell proliferation marker)
* Elastin and glycosaminoglycan content
* Gene expression (collagen I & III mRNA)
* Tissue dry mass and regeneration rate

⸻

Results

GHK-Cu produced:

* Increased collagen synthesis and extracellular matrix deposition
* Elevated cell proliferation markers (DNA content increase)
* Upregulated collagen I and III gene expression
* Increased glycosaminoglycan and dermatan sulfate content
* Enhanced overall wound tissue regeneration

Notably: strong shift toward matrix remodelling and structural repair signalling.

⸻

4. KPV – Inflammatory Regulation (Rodent & Cellular Models)

Study objective

To evaluate KPV (lysine-proline-valine), a tripeptide derived from α-MSH, in inflammatory suppression models, particularly gut epithelial and immune signalling systems.

⸻

Methods

Models included:

* Intestinal epithelial inflammation models
* Immune cell cytokine response assays
* Barrier disruption experimental systems

Measured outcomes:

* NF-κB inflammatory signalling activity
* Cytokine release (IL-6, TNF-α in model systems)
* Epithelial barrier integrity markers

⸻

Results

KPV demonstrated:

* Suppression of NF-κB mediated inflammatory signalling
* Reduced pro-inflammatory cytokine expression in model systems
* Improved epithelial barrier stability in injury conditions
* Dampening of acute inflammatory cascade activation

Core effect: anti-inflammatory modulation via innate immune signalling pathways.

⸻

Integrated Mechanistic Interpretation (Theoretical Only)

Based on independent animal models (not combination testing), the KLOW stack is theoretically associated with four complementary biological axes:

* BPC-157 → vascular protection + tissue healing acceleration
* TB-500 → cell migration + wound closure + anti-fibrotic remodelling
* GHK-Cu → extracellular matrix synthesis + gene expression modulation
* KPV → inflammatory suppression via NF-κB pathway downregulation

⸻

Overall Preclinical Interpretation

Across all individual peptide studies, the KLOW stack components collectively demonstrate:

* Enhanced tissue repair signalling in multiple organ systems (GI, skin, tendon, cardiac)
* Increased angiogenesis and vascular remodelling in injury environments
* Modulation of inflammatory response pathways
* Acceleration of cell migration and extracellular matrix reconstruction

However:

* There is no in vivo evidence validating additive or synergistic effects of the four peptides combined
* All stack-level conclusions remain mechanistic extrapolations from single-agent studies only